NCT00219882 (SEER) is a Phase 1 clinical trial of standardized turmeric root extract in Cystic Fibrosis, sponsored by Ramsey, Bonnie, MD.

Who is sponsoring NCT00219882?

NCT00219882 is sponsored by Ramsey, Bonnie, MD.

What drugs are being tested in NCT00219882?

Interventions in NCT00219882: standardized turmeric root extract.

What condition does NCT00219882 study?

NCT00219882 studies Cystic Fibrosis.

Is NCT00219882 still recruiting?

NCT00219882 is currently completed. Last updated 18 December 2007.

Last reviewed 2007-12-18 · How we verify

NCT00219882: SEER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Safety and Dose Finding Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis Who Are Homozygous for Delta F508 Cystic Fibrosis Transmembrane Conductance Regulator (ΔF508 CFTR) Mutation

Completed Phase 1 Last updated 18 December 2007

What this trial tests

Phase 1 trial testing standardized turmeric root extract in Cystic Fibrosis in 11 participants. Completed in 1 January 2006.

Timeline

1 April 2005

1 January 2006

Quick facts

Lead sponsor	Ramsey, Bonnie, MD
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	1 April 2005
Estimated completion	1 January 2006
Sites	2 locations across United States

Drugs / interventions tested

standardized turmeric root extract — full drug profile →

Conditions studied

Cystic Fibrosis — all drugs for Cystic Fibrosis →

Sponsor

Ramsey, Bonnie, MD — full company profile →

Who can join

Adults 18 to 40, any sex, with Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Safety and tolerability of 14 days of treatment with orally administered curcuminoids as assessed by adverse events, laboratory parameters, and spirometry.
Time frame: 14 days

Sponsor's own description

The purpose of this study is to assess the safety of advancing doses of curcuminoids administered orally for fourteen consecutive days in adult subjects with cystic fibrosis (CF) who are homozygous for ΔF508 CFTR.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Trials with 'epigenetic' drugs: an update.
Nebbioso A, Carafa V, Benedetti R, Altucci L. · · 2012 · cited 162× · PMID 23103179 · DOI 10.1016/j.molonc.2012.09.004
Reconnoitering the Therapeutic Role of Curcumin in Disease Prevention and Treatment: Lessons Learnt and Future Directions.
Sivani BM, Azzeh M, Patnaik R, Pantea Stoian A, et al · · 2022 · cited 26× · PMID 35888763 · DOI 10.3390/metabo12070639
The F508del-CFTR trafficking correctors elexacaftor and tezacaftor are CFTR-independent Ca<sup>2+</sup>-mobilizing agonists normalizing abnormal Ca<sup>2+</sup> levels in human airway epithelial cells.
Lévêque M, Mirval S, Barrault C, Fixe I, et al · · 2024 · cited 3× · PMID 39702307 · DOI 10.1186/s12931-024-03059-8

Verify or expand the search:

Other recruiting trials for Cystic Fibrosis

Currently open trials in the same condition.

NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00219882 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ramsey, Bonnie, MD
Last refreshed: 18 December 2007

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00219882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing